메뉴 건너뛰기




Volumn 8, Issue 1, 2018, Pages

Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis

Author keywords

[No Author keywords available]

Indexed keywords

CHENODEOXYCHOLIC ACID; MC4R PROTEIN, MOUSE; MELANOCORTIN 4 RECEPTOR; OBETICHOLIC ACID; PROTEIN P53;

EID: 85047817579     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-26383-8     Document Type: Article
Times cited : (65)

References (49)
  • 2
    • 84878930738 scopus 로고    scopus 로고
    • Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
    • Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10, 330-344, https://doi.org/10.1038/nrgastro.2013.41 (2013).
    • (2013) Nat Rev Gastroenterol Hepatol , vol.10 , pp. 330-344
    • Anstee, Q.M.1    Targher, G.2    Day, C.P.3
  • 3
    • 84864390922 scopus 로고    scopus 로고
    • The epidemiology, pathogenesis and histopathology of fatty liver disease
    • Levene, A. P. & Goldin, R. D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 61, 141-152, https://doi.org/10.1111/j.1365-2559.2011.04145.x (2012).
    • (2012) Histopathology , vol.61 , pp. 141-152
    • Levene, A.P.1    Goldin, R.D.2
  • 4
    • 0042165989 scopus 로고    scopus 로고
    • Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
    • Feldstein, A. E. et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437-443 (2003).
    • (2003) Gastroenterology , vol.125 , pp. 437-443
    • Feldstein, A.E.1
  • 5
    • 84861543083 scopus 로고    scopus 로고
    • The diagnosis and management of non-Alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
    • Chalasani, N. et al. The diagnosis and management of non-Alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005-2023, https://doi.org/10.1002/hep.25762 (2012).
    • (2012) Hepatology , vol.55 , pp. 2005-2023
    • Chalasani, N.1
  • 6
    • 0029046931 scopus 로고
    • Identification of a nuclear receptor that is activated by farnesol metabolites
    • Forman, B. M. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687-693 (1995).
    • (1995) Cell , vol.81 , pp. 687-693
    • Forman, B.M.1
  • 7
    • 1542513682 scopus 로고    scopus 로고
    • Expression and activation of the farnesoid X receptor in the vasculature
    • Bishop-Bailey, D., Walsh, D. T. & Warner, T. D. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 101, 3668-3673, https://doi.org/10.1073/pnas.0400046101 (2004).
    • (2004) Proc Natl Acad Sci USA , vol.101 , pp. 3668-3673
    • Bishop-Bailey, D.1    Walsh, D.T.2    Warner, T.D.3
  • 8
    • 0034664729 scopus 로고    scopus 로고
    • Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
    • Sinal, C. J. et al. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis. Cell 102, 731-744, https://doi.org/10.1016/S0092-8674(00)00062-3 (2000).
    • (2000) Cell , vol.102 , pp. 731-744
    • Sinal, C.J.1
  • 9
    • 67649210759 scopus 로고    scopus 로고
    • Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-Alcoholic steatohepatitis
    • Zhang, S., Wang, J., Liu, Q. & Harnish, D. C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-Alcoholic steatohepatitis. J Hepatol 51, 380-388, https://doi.org/10.1016/j.jhep.2009.03.025 (2009).
    • (2009) J Hepatol , vol.51 , pp. 380-388
    • Zhang, S.1    Wang, J.2    Liu, Q.3    Harnish, D.C.4
  • 10
    • 84877916062 scopus 로고    scopus 로고
    • Ageing FXR deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH
    • Bjursell, M. et al. Ageing FXR deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One 8, e64721, https://doi.org/10.1371/journal.pone.0064721 (2013).
    • (2013) PLoS One , vol.8 , pp. e64721
    • Bjursell, M.1
  • 11
    • 0037101810 scopus 로고    scopus 로고
    • 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
    • Pellicciari, R. et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45, 3569-3572 (2002).
    • (2002) J Med Chem , vol.45 , pp. 3569-3572
    • Pellicciari, R.1
  • 12
    • 84996521986 scopus 로고    scopus 로고
    • Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice
    • Haczeyni, F. et al. Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. Obesity 25, 155-165, https://doi.org/10.1002/oby.21701 (2017).
    • (2017) Obesity , vol.25 , pp. 155-165
    • Haczeyni, F.1
  • 13
    • 85021683795 scopus 로고    scopus 로고
    • Farnesoid X receptor induces Takeda G-protein receptor 5 cross-Talk to regulate bile acid synthesis and hepatic metabolism
    • Pathak, P. et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-Talk to regulate bile acid synthesis and hepatic metabolism. J Biol Chem 292, 11055-11069, https://doi.org/10.1074/jbc.M117.784322 (2017).
    • (2017) J Biol Chem , vol.292 , pp. 11055-11069
    • Pathak, P.1
  • 14
    • 77950613528 scopus 로고    scopus 로고
    • FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
    • Cipriani, S., Mencarelli, A., Palladino, G. & Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 51, 771-784, https://doi.org/10.1194/jlr.M001602 (2010).
    • (2010) J Lipid Res , vol.51 , pp. 771-784
    • Cipriani, S.1    Mencarelli, A.2    Palladino, G.3    Fiorucci, S.4
  • 15
    • 85017474560 scopus 로고    scopus 로고
    • MiR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
    • e2748 10.1038/cddis.2017.172 28406477 5477590
    • Rodrigues, P. M. et al. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis 8, e2748, https://doi.org/10.1038/cddis.2017.172 (2017).
    • (2017) Cell Death Dis , vol.8
    • Rodrigues, P.M.1
  • 16
    • 22944449688 scopus 로고    scopus 로고
    • A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis
    • Fiorucci, S. et al. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 314, 584-595, https://doi.org/10.1124/jpet.105.084905 (2005).
    • (2005) J Pharmacol Exp Ther , vol.314 , pp. 584-595
    • Fiorucci, S.1
  • 17
    • 84988001263 scopus 로고    scopus 로고
    • FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
    • Verbeke, L. et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep 6, 33453, https://doi.org/10.1038/srep33453 (2016).
    • (2016) Sci Rep , vol.6
    • Verbeke, L.1
  • 18
    • 7644244675 scopus 로고    scopus 로고
    • The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis
    • Fiorucci, S. et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497-1512 (2004).
    • (2004) Gastroenterology , vol.127 , pp. 1497-1512
    • Fiorucci, S.1
  • 19
    • 84880664792 scopus 로고    scopus 로고
    • Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease
    • Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574-582.e571, https://doi.org/10.1053/j.gastro.2013.05.042 (2013).
    • (2013) Gastroenterology , vol.145 , pp. 574-582
    • Mudaliar, S.1
  • 20
    • 84929266699 scopus 로고    scopus 로고
    • Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial
    • Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 385, 956-965, https://doi.org/10.1016/S0140-6736(14)61933-4 (2015).
    • (2015) Lancet , vol.385 , pp. 956-965
    • Neuschwander-Tetri, B.A.1
  • 21
    • 84982102773 scopus 로고    scopus 로고
    • A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
    • Nevens, F. et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 375, 631-643, https://doi.org/10.1056/NEJMoa1509840 (2016).
    • (2016) N Engl J Med , vol.375 , pp. 631-643
    • Nevens, F.1
  • 22
    • 80055004124 scopus 로고    scopus 로고
    • Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis
    • Itoh, M. et al. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol 179, 2454-2463, https://doi.org/10.1016/j.ajpath.2011.07.014 (2011).
    • (2011) Am J Pathol , vol.179 , pp. 2454-2463
    • Itoh, M.1
  • 23
    • 27544450765 scopus 로고    scopus 로고
    • Divergence of melanocortin pathways in the control of food intake and energy expenditure
    • Balthasar, N. et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123, 493-505, https://doi.org/10.1016/j.cell.2005.08.035 (2005).
    • (2005) Cell , vol.123 , pp. 493-505
    • Balthasar, N.1
  • 24
    • 84892425701 scopus 로고    scopus 로고
    • Hepatic crown-like structure: A unique histological feature in non-Alcoholic steatohepatitis in mice and humans
    • Itoh, M. et al. Hepatic crown-like structure: A unique histological feature in non-Alcoholic steatohepatitis in mice and humans. PLoS One 8, e82163, https://doi.org/10.1371/journal.pone.0082163 (2013).
    • (2013) PLoS One , vol.8 , pp. e82163
    • Itoh, M.1
  • 25
    • 85015282883 scopus 로고    scopus 로고
    • Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis
    • Komiya, C. et al. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci Rep 7, 44754, https://doi.org/10.1038/srep44754 (2017).
    • (2017) Sci Rep , vol.7
    • Komiya, C.1
  • 26
    • 84926351030 scopus 로고    scopus 로고
    • Eicosapentaenoic acid ameliorates non-Alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice
    • Konuma, K. et al. Eicosapentaenoic acid ameliorates non-Alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. PLoS One 10, e0121528, https://doi.org/10.1371/journal.pone.0121528 (2015).
    • (2015) PLoS One , vol.10 , pp. e0121528
    • Konuma, K.1
  • 27
    • 84956731915 scopus 로고    scopus 로고
    • Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining
    • Yoshimura, K. et al. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology 63, 462-473, https://doi.org/10.1002/hep.28226 (2016).
    • (2016) Hepatology , vol.63 , pp. 462-473
    • Yoshimura, K.1
  • 28
    • 84871221881 scopus 로고    scopus 로고
    • MiR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-Alcoholic fatty liver disease
    • Castro, R. E. et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-Alcoholic fatty liver disease. J Hepatol 58, 119-125, https://doi.org/10.1016/j.jhep.2012.08.008 (2013).
    • (2013) J Hepatol , vol.58 , pp. 119-125
    • Castro, R.E.1
  • 29
    • 84880925312 scopus 로고    scopus 로고
    • Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-Alcoholic fatty liver disease
    • Derdak, Z. et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-Alcoholic fatty liver disease. J Hepatol 58, 785-791, https://doi.org/10.1016/j.jhep.2012.11.042 (2013).
    • (2013) J Hepatol , vol.58 , pp. 785-791
    • Derdak, Z.1
  • 30
    • 79961010787 scopus 로고    scopus 로고
    • Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice
    • Kodama, T. et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 121, 3343-3356, https://doi.org/10.1172/jci44957 (2011).
    • (2011) J Clin Invest , vol.121 , pp. 3343-3356
    • Kodama, T.1
  • 31
    • 85046423533 scopus 로고    scopus 로고
    • CD11c+ resident macrophages drive hepatocyte death-Triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis
    • Itoh, M. et al. CD11c+ resident macrophages drive hepatocyte death-Triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis. JCI Insight 2, https://doi.org/10.1172/jci.insight.92902 (2017).
    • (2017) JCI Insight , vol.2
    • Itoh, M.1
  • 32
    • 85010966335 scopus 로고    scopus 로고
    • The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
    • Schwabl, P. et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol 66, 724-733, https://doi.org/10.1016/j.jhep.2016.12.005 (2017).
    • (2017) J Hepatol , vol.66 , pp. 724-733
    • Schwabl, P.1
  • 33
    • 84901605121 scopus 로고    scopus 로고
    • Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
    • Verbeke, L. et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59, 2286-2298, https://doi.org/10.1002/hep.26939 (2014).
    • (2014) Hepatology , vol.59 , pp. 2286-2298
    • Verbeke, L.1
  • 34
    • 33750628734 scopus 로고    scopus 로고
    • Expression ofp53, Bax and Bcl-2 proteins in hepatocytes in non-Alcoholic fatty liver disease
    • Panasiuk, A., Dzieciol, J., Panasiuk, B. & Prokopowicz, D. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-Alcoholic fatty liver disease. World J Gastroenterol 12, 6198-6202 (2006).
    • (2006) World J Gastroenterol , vol.12 , pp. 6198-6202
    • Panasiuk, A.1    Dzieciol, J.2    Panasiuk, B.3    Prokopowicz, D.4
  • 35
    • 63049134573 scopus 로고    scopus 로고
    • Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression
    • Farrell, G. C. et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol 24, 443-452, https://doi.org/10.1111/j.1440-1746.2009.05785.x (2009).
    • (2009) J Gastroenterol Hepatol , vol.24 , pp. 443-452
    • Farrell, G.C.1
  • 36
    • 84862700968 scopus 로고    scopus 로고
    • Cross-regulation of protein stability by p53 and nuclear receptor SHP
    • Yang, Z., Zhang, Y., Kemper, J. K. & Wang, L. Cross-regulation of protein stability by p53 and nuclear receptor SHP. PLoS One 7, e39789, https://doi.org/10.1371/journal.pone.0039789 (2012).
    • (2012) PLoS One , vol.7 , pp. e39789
    • Yang, Z.1    Zhang, Y.2    Kemper, J.K.3    Wang, L.4
  • 37
    • 43049163953 scopus 로고    scopus 로고
    • Acetylation is indispensable for p53 activation
    • Tang, Y., Zhao, W., Chen, Y., Zhao, Y. & Gu, W. Acetylation is indispensable for p53 activation. Cell 133, 612-626, https://doi.org/10.1016/j.cell.2008.03.025 (2008).
    • (2008) Cell , vol.133 , pp. 612-626
    • Tang, Y.1    Zhao, W.2    Chen, Y.3    Zhao, Y.4    Gu, W.5
  • 38
    • 77955418479 scopus 로고    scopus 로고
    • The C terminus of p53 binds the N-Terminal domain of MDM2
    • Poyurovsky, M. V. et al. The C terminus of p53 binds the N-Terminal domain of MDM2. Nat Struct Mol Biol 17, 982-989, https://doi.org/10.1038/nsmb.1872 (2010).
    • (2010) Nat Struct Mol Biol , vol.17 , pp. 982-989
    • Poyurovsky, M.V.1
  • 39
  • 40
    • 84866348839 scopus 로고    scopus 로고
    • P53/p66Shc-mediated signaling contributes to the progression of non-Alcoholic steatohepatitis in humans and mice
    • Tomita, K. et al. p53/p66Shc-mediated signaling contributes to the progression of non-Alcoholic steatohepatitis in humans and mice. J Hepatol 57, 837-843, https://doi.org/10.1016/j.jhep.2012.05.013 (2012).
    • (2012) J Hepatol , vol.57 , pp. 837-843
    • Tomita, K.1
  • 41
    • 84922322650 scopus 로고    scopus 로고
    • Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3
    • Wang, Y. D. et al. Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3. Mol Endocrinol 29, 322-331, https://doi.org/10.1210/me.2014-1225 (2015).
    • (2015) Mol Endocrinol , vol.29 , pp. 322-331
    • Wang, Y.D.1
  • 42
    • 85028468258 scopus 로고    scopus 로고
    • Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage
    • Gai, Z. et al. Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage. Sci Rep 7, 9815, https://doi.org/10.1038/s41598-017-10168-6 (2017).
    • (2017) Sci Rep , vol.7
    • Gai, Z.1
  • 43
    • 84863502669 scopus 로고    scopus 로고
    • Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis
    • Tanaka, N., Matsubara, T., Krausz, K. W., Patterson, A. D. & Gonzalez, F. J. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 56, 118-129, https://doi.org/10.1002/hep.25630 (2012).
    • (2012) Hepatology , vol.56 , pp. 118-129
    • Tanaka, N.1    Matsubara, T.2    Krausz, K.W.3    Patterson, A.D.4    Gonzalez, F.J.5
  • 44
    • 84879888338 scopus 로고    scopus 로고
    • Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
    • Yoshimoto, S. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97-101, https://doi.org/10.1038/nature12347 (2013).
    • (2013) Nature , vol.499 , pp. 97-101
    • Yoshimoto, S.1
  • 45
    • 84894875873 scopus 로고    scopus 로고
    • Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice
    • Tomita, K. et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 59, 154-169, https://doi.org/10.1002/hep.26604 (2014).
    • (2014) Hepatology , vol.59 , pp. 154-169
    • Tomita, K.1
  • 46
    • 84942878841 scopus 로고    scopus 로고
    • New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond
    • Beuers, U., Trauner, M., Jansen, P. & Poupon, R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 62, S25-37, https://doi.org/10.1016/j.jhep.2015.02.023 (2015).
    • (2015) J Hepatol , vol.62 , pp. S25-37
    • Beuers, U.1    Trauner, M.2    Jansen, P.3    Poupon, R.4
  • 47
    • 84864861866 scopus 로고    scopus 로고
    • Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
    • Porez, G., Prawitt, J., Gross, B. & Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 53, 1723-1737, https://doi.org/10.1194/jlr.R024794 (2012).
    • (2012) J Lipid Res , vol.53 , pp. 1723-1737
    • Porez, G.1    Prawitt, J.2    Gross, B.3    Staels, B.4
  • 49
    • 78650953709 scopus 로고    scopus 로고
    • Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease
    • Juluri, R. et al. Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol 45, 55-58, https://doi.org/10.1097/MCG.0b013e3181dd1348 (2011).
    • (2011) J Clin Gastroenterol , vol.45 , pp. 55-58
    • Juluri, R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.